Conference on Retroviruses and Opportunistic Infections (CROI 2020)
17 April 2020. Related: Conference reports.
CROI 27 (virtual) 2020
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
17 April 2020. Related: Conference reports, Side effects.
Dolutegravir-based ART is safe and effective for pregnant women: first results from the VESTED trial
17 April 2020. Related: Conference reports, Pregnancy.
A step forward for AAV-mediated delivery of bNAbs
17 April 2020. Related: Conference reports, Cure-related research, Basic science and immunology.
Conference on Retroviruses and Opportunistic Infections (CROI 2020)
12 March 2020. Related: Conference reports.
CROI 2020: Special session on COVID-19
12 March 2020. Related: Conference reports, Virology, COVID-19: pathogenesis, COVID-19: on the web.
Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
12 March 2020. Related: Conference reports, Antiretrovirals.
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
12 March 2020. Related: Conference reports, Side effects.
London patient is second person to be cured of HIV from allogeneic stem-cell transplant
12 March 2020. Related: Conference reports, Cure-related research.
The London Patient tells his story as second person cured of HIV
12 March 2020. Related: Conference reports, Cure-related research.